Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock

NEWARK, Calif.: NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,046,358 shares of its common stock at a price to the public of $37.75 per share. Gross proceeds to...

Click to view original post